Program
12:00 – 14:00
REGISTRATION
14:00 – 14:10
WELCOME ADDRESS
14:10 – 15:50
SESSION 1: REAL-WORLD EXPERIENCE, NOVEL CLINICAL APPROACHES AND COMBINATION THERAPIES
14:10 – 14:35
KEYNOTE LECTURE: CONQUERING RESISTANCE MECHANISMS IN ENGINEERED CELL THERAPIES
Stan Riddell, Fred Hutchinson Cancer Research Center, USA
14:35 -14:50
RWE: BEYOND CRS AND ICANS: HEMATOTOXICITY AND INFECTIONS AS DRIVERS OF CAR-T NRM
Marion Subklewe, LETSimmun Consortium, Germany
14:50 – 15:05
CLINICAL LEARNINGS AND NEW FRONTIERS FOR B CELL-DRIVEN DISEASES
Jennifer Brogdon, Novartis, USA
15:05 – 15:45
Panel discussion
15:50 – 16:30
COFFEE BREAK, YOUNG SCIENTIST FORUM, EXHIBITION & POSTER VIEWING
15:55 – 16:25
THE RESEARCHER’S JOURNEY: OVERCOMING EARLY CAREER CHALLENGES
Moderator: Stanley Riddell, Fred Hutchinson Cancer Research Center, USA
Young scientists:
Alon Richter, Tel Aviv University, Israel
Sophia Stock, Ludwig Maximilian University of Munich, Germany
Bettina Bernard, Technical University of Munich, Germany
Faculty members:
Marion Subklewe, LETSimmun Consortium, Germany
Hans Stauss, University College London, UK
Chiara Bonini, Vita-Salute San Raffaele University, Italy
16:30 – 18:15
SESSION 2: SUPERPOWERED LYMPHOCYTES
16:30 – 16:45
A PRIVATE CROSSTALK ESTABLISHED BY TUMOR-TARGETED CYTOKINE RELEASE RESCUES CAR-T ACTIVITY AND ENGAGES HOST T-CELLS AGAINST GLIOBLASTOMA
Luigi Naldini, San Raffaele Telethon Institute for Gene Therapy, Italy
16:45 – 17:00
ENGINEERING T-CELLS FOR SUPERIOR PERFORMANCE
George Coukos, Ludwig Cancer Research Lausanne Branch, Switzerland
17:00 – 17:15
OVERCOMING T-CELL SENESCENCE BY GENOME EDITING
Chiara Bonini, Vita-Salute San Raffaele University, Italy
17:15 – 17:25
STAB-T-CELLS SECRETING ANTI-BCMA T-CELL ENGAGERS DEMONSTRATE SUPERIOR ANTITUMOR ACTIVITY COMPARED TO ANTI-BCMA CAR T-CELLS
Javier Arroyo-Rodenas, University Hospital October 12, Spain
17:25 – 17:35
T-CELL-MEDIATED ADCC AS A THERAPEUTIC STRATEGY FOR SOLID CANCERS
Yaron Carmi, Tel Aviv University, Israel
17:35 – 17:45
ADDRESSING TUMOUR MICROENVIRONMENT RESISTANCE MECHANISMS TO IMPROVE CAR T-CELL EFFICACY
Paul Neeson, Peter MacCallum Cancer Centre, Australia
17:45 – 18:15
Panel discussion
18:15 – 20:00
MEET THE POSTER PRESENTERS & WELCOME RECEPTION
09:00 – 10:10
SESSION 3: NON-VIRAL CAR/TCR GENE TARGETING
09:00 – 09:15
COMBINING CRISPR AND TRANSPOSON-BASED TECHNOLOGIES FOR IMPROVED CAR-T THERAPIES
Juan Roberto Rodriguez-Madoz, Cima Universidad de Navarra, Spain
09:15 – 09:30
CAR-TS GOING NON-VIRAL FROM BENCH TO BEDSIDE (AND BACK)
Michael Hudecek, LETSimmun Consortium, Germany
09:30 – 09:40
CELL AVIDITY NEXT GENERATION BINDING: UNDERSTAND THE MECHANISM OF ACTION THROUGH CELL-CELL BINDING
TBА
09:40 – 10:10
Panel Discussion
10:10 – 10:50
COFFEE BREAK, EXHIBITION, INDUSTRY PRESENTATIONS & POSTER VIEWING
10:50 – 12:20
SESSION 4: CUTTING-EDGE INDUSTRY ADVANCEMENTS
10:50 – 11:20
ENHANCING CELL THERAPY MANUFACTING: SCALABLE AND FLEXIBLE SOLUTIONS FOR T CELL ISOLATION
TBA
11:20 – 11:35
AUTOMATED, SCALABLE IMMUNE CELL CIRCULATION PLATFORM FOR CANCER MODELS
Mark Lyons, Hooke Bio, Ireland
11:35 – 11:50
MOLECULAR PIXELATION QUANTIFIES CAR T ACTIVITY AND REVEALS CANCER – SPECIFIC PROTEIN PATTERNS OF INDIVIDUAL CELLS
Hanna van Ooijen, Pixelgen Technologies, Sweden
11:50 – 12:20
Panel Discussion
12:20 – 13:50
LUNCH BREAK, TOP 10 POSTER PRESENTATIONS, EXHIBITION & POSTER VIEWING
13:50 – 15:15
SESSION 5: CAR/TCR MRNA THERAPIES
13:50 – 14:15
KEYNOTE LECTURE: NUCLEOSIDE-MODIFIED mRNA-LNP THERAPEUTICS
Drew Weissman, University of Pennsylvania School of Medicine, USA
14:15 – 14:30
MRNA-BASED T-CELL ENGINEERING FOR VIRUS-RELATED CANCERS (HBV-HCC) AND VIRAL INFECTIONS
Antonio Bartoletti, A*STAR, Singapore
14:30 – 14:40
ANTIGEN-SPECIFIC AND BYSTANDER ANTITUMOR ACTIVITY OF RNA CAR T-CELLS AGAINST GBM-ASSOCIATED ANTIGEN PTPRZ1
Darel Martínez Bedoya, University of Geneva, Switzerland
14:40 – 15:15
Panel Discussion
15:15 – 15:25
SHORT BREAK
15:25 – 16:35
SESSION 6: UNIVERSAL DONOR CELLS & ADVANCED TCR ENGINEERING
15:25 – 15:40
TARGETING CANCER WITH T-CELL RECEPTOR-ENGINEERED T-CELLS
Johanna Olweus, Oslo University, Norway
15:40 – 15:55
TARGETED ENGINEERING OF RECOMBINANT TCR-T CELLS FOR THERAPY AND LIGAND PREDICTION
Dirk Busch, Technical University of Munich, Germany
15:55 – 16:05
DISRUPTED KINASE (DISK) CAR T-CELLS FOR ALLOGENEIC THERAPY
Previtha Dawn Sakthi Vale, National University of Singapore, Singapore
16:05 – 16:35
Panel Discussion
16:35 – 17:30
COFFEE BREAK, EXPERT-LED INSIGHTS, EXHIBITION & POSTER VIEWING
16:50 – 17:20
EXPERT-LED INSPIRATION: YOUR QUESTIONS, OUR INSIGHTS
Moderator: Stanley Riddell, Fred Hutchinson Cancer Research Center, USA
Discussants:
Drew Weissman, University of Pennsylvania School of Medicine, USA
Carl June, University of Pennsylvania, USA
17:30 – 19:10
SESSION 7: UPDATED CLINICAL DATA & NOVEL DEVELOPMENTS
17:30 – 17:55
KEYNOTE LECTURE: CAR T-CELLS – CURRENT STATUS AND OUTLOOK
Carl June, University of Pennsylvania, USA
17:55 – 18:10
ENGINEERING DE NOVO BINDER CAR-T CELL THERAPIES WITH GENERATIVE AI
Andrea Schmidts, Technical University of Munich, Germany
18:10 – 18:20
ALLOREACTIVE VERSUS IL-15 EX-VIVO-STIMULATED NK CELLS AS ADOPTIVE CELL THERAPY IN HAPLOIDENTICAL TRANSPLANTATION FOR PEDIATRIC ACUTE LEUKEMIA: A PHASE I/II TRIAL (PHINK)
Carmen Mestre-Durán, Research Institute of the University Hospital La Paz (IdiPAZ), Spain
18:20 – 19:00
Panel discussion
08:30 – 09:30
SESSION 8: BEYOND ALPHA-BETA T-CELLS
08:30 – 08:45
FROM AUTOLOGOUS TO ALLOGENEIC CAR EFFECTOR CELLS: PUSHING THE BOUNDARIES FROM CANCER TO OTHER SEVERE DISEASES
Ulrike Kohl, Fraunhofer Institute for Cell Therapy and Immunology Leipzig, Germany
08:45 – 08:55
HSPC GENE EDITING FOR SPECIFIC ANTIBODY EXPRESSION THROUGH HUMORAL IMMUNE RESPONSES
Harald Hartweger, The Rockefeller University, United States
08:55 – 09:05
REPROGRAMING IMMUNOSUPPRESSIVE MICROENVIRONMENT IN THE SOLID TUMOR BY TARGETED DELIVERY OF TGF-Β-BLOCKING SCFV FROM ANTIBODY-CAR-MACROPHAGES (AB-CAR-M)
Rio Sugimura, Hong Kong University, Hong Kong
09:05 – 09:30
Panel discussion
09:30 – 11:00
SESSION 9: TARGETING NON-MALIGNANT DISEASES
09:30 – 09:45
CAR T-CELL TREATMENT IN AUTOIMMUNE DISEASE
Georg Schett, Friedrich-Alexander University of Erlangen-Nuremberg, Germany
09:45 – 10:00
CAR T-CELLS AGAINST IgE B CELLS
Adi Barzel, Tel Aviv University, Israel
10:00 – 10:15
MODIFICATION OF TCR/CD3 TO ENHANCE T-CELL FUNCTION
Hans Stauss, University College London, UK
10:15 – 10:30
TBA
Samik Basu, Cabaletta, USA
10:30 – 10:40
BASE EDITING OF APDS1 AND APDS2 T-CELLS RESTORES PI3K DELTA SIGNALLING
Kate Orf, UCL, United Kingdom
10:40 – 11:00
Panel discussion
11:00 – 11:40
COFFEE BREAK, EXHIBITION & POSTER PRESENTATIONS
11:40 – 12:40
SESSION 10: SELECTED ABSTRACTS FOR ORAL PRESENTATION
11:40 – 11:50
RAPID MACHINE LEARNING DRIVEN TARGET IDENTIFICATION IN TIL AND PERSONALISED TRANSGENIC TCR CELL THERAPIES
Edward Green, DKFZ, Germany
11:50 – 12:00
OVERCOMING BARRIERS FOR T-CELL THERAPY OF CHRONIC HEPATITIS B VIRUS INFECTION
Lisa Schiller, Technical University of Munich, Germany
12:00 – 12:10
SYSTEMIC DELIVERY OF CDH17 CAR T-CELLS ALLOWS EFFECTIVE AND SAFE TARGETING OF COLORECTAL CANCER LIVER METASTASES
Rita El Khoury, IRCCS San Raffaele Scientific Institute, Italy
12:10 – 12:20
DUAL TARGETING OF PD-L1 AND ERBB2 BY CAR-NK CELLS ENABLES SPECIFIC ELIMINATION OF SOLID TUMOR CELLS AND OVERCOMES IMMUNE ESCAPE VIA ANTIGEN LOSS
Jiri Eitler, Technical University of Dresden, Germany
12:20 – 12:40
Panel Discussion
12:40 – 13:40
SESSION 11: IN VIVO AND BEDSIDE T-CELL ENGINEERING
12:40 – 12:55
T-CELL TARGETED VECTORS FOR IN VIVO CAR DELIVERY
Christian Buchholz, PEI, Germany
12:55 – 13:10
EXTRACORPOREAL CAR GENE DELIVERY
David Peritt, Lupagen, USA
13:10 – 13:25
NOVEL NON-VIRAL DNA-BASED GENE THERAPY VECTOR FOR CAR T ENGINEERING IN VIVO
Jacek Lubelski, NanoCell, Netherlands
13:25 – 13:45
Panel Discussion
13:45 – 14:00
BEST POSTER ANNOUNCEMENT & CONFERENCE CLOSURE
Moderators: Adi Barzel, Tel-Aviv University, Israel
Dirk Busch, Technical University of Munich, Germany